Accuray Incorporated (ARAY)

Accuray Incorporated Reports Inducement Award Under NASDAQ Listing RulesMay 29, 2026 4:10 PM
PR Newswire (US) MADISON, Wis., May 29, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company's new Chief Commercial Officer and David Shin, the company's new Chief Legal Officer. As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the "Inducement Awards"). The Inducement Awards were made outside of the company's current equity plan but are subject to terms and conditions generally consistent with those in the company's Stand-Alone Inducement Restricted Stock Unit Agreement and the company's 2026 Equity Incentive Plan.Paul Miele Inducement Award
Mr. Miele was granted 650,000 restricted stock units ("RSUs") covering shares of the company's common stock. One fourth (1/4) of the underlying shares subject to the RSU award will vest on April 30, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Miele's continued employment through the applicable vesting date.In addition, Mr. Miele was granted 650,000 performance based restricted stock units ("PSUs") (at target) covering shares of the company's common stock. The PSUs have a performance period ending on the last day of the company's 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Board of Directors or its Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives, subject to Mr. Miele's continued employment and the terms of the applicable award agreement.David Shin Inducement Award
Mr. Shin was granted 375,000 restricted stock units ("RSUs") covering shares of the company's common stock. One-fourth (1/4) of the underlying shares subject to the RSU award will vest on January 29, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Shin's continued employment through the applicable vesting date.In addition, Mr. Shin was granted 375,000 performance based restricted stock units ("PSUs") (at target) covering shares of the company's common stock. The PSUs have a performance period ending on the last day of the company's 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives of the company, subject to Mr. Shin's continued employment and the terms of the applicable award agreement.About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.Media Contact
Taylor Bould
Communications Specialist, Accuray
+1 (608) 830-3604
tbould@accuray.com View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-302786070.htmlSOURCE Accuray Incorporated Original: Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

ARAY..................................a/h

Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with CancerMay 15, 2026 4:05 PM
PR Newswire (US) MADISON, Wis., May 15, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health (UW SMPH) announced a new 10-year strategic collaboration to advance personalized cancer treatments using Accuray's Stellar™ adaptive radiation therapy platform. This agreement builds on longstanding shared history of partnership between Accuray and the school to develop precision radiation therapy technologies using imaging to precisely deliver dose sculpting for cancer treatments. This newest collaboration will support clinical research, education and training, and the development of adaptive therapies that help empower medical care teams to continually raise the standard in cancer care. "Our success depends on collaboration, innovation, and the energy that comes from addressing meaningful clinical needs for patients," said Steve La Neve, President and CEO of Accuray. "This Master Research Agreement formalizes and expands our longstanding relationship with the University of Wisconsin–Madison and grounds our innovations in real-world clinical practice and impactful patient care. By leveraging our respective strengths, we aim to extend the curative power of radiotherapy so departments of all sizes around the world can benefit from advanced adaptive therapies."In the late 1980s, University of Wisconsin-Madison Professor of Medical Physics, Human Oncology, and Engineering Thomas "Rock" Mackie and his team invented technology that would later be commercialized as Accuray's first helical radiation delivery platform, the TomoTherapy® System. This ushered in a new era in radiation medicine, enabling clinicians for the first time to integrate helical 3D image-guidance with intensity-modulated radiation therapy (IG-IMRT), increasing treatment precision and accuracy to help improve patients' cancer care. Since its introduction, Accuray has continued to enhance the helical platform, introducing advances in image quality, speed, versatility, and workflow efficiency.The new agreement between the UW School of Medicine and Public Health and Accuray will build on this shared history to advance the next generation of adaptive radiotherapy approaches, according to Zachary Morris, MD, PhD, professor and chair of human oncology.  "At UW we have exceptionally talented innovators in radiation medicine across the spectrum from discovery science to translational and clinical research and we have a track-record of advancing discoveries to clinical practice. This agreement with Accuray is an exciting next step that will accelerate the process of translating research innovation into technologies that better serve patients, leveraging a robust academic-industry collaboration to advance personalized radiotherapy treatments," said Morris. "This framework enables us to build on a long history of shared innovation with Accuray to deepen our collaboration, bring future innovations from bench to bedside, and create translational research and training opportunities that keep patients at the center of our work," said Nita Ahuja, MD, MBA, Dean of the UW School of Medicine and Public Health and Vice Chancellor for Medical Affairs at the University of Wisconsin–Madison.About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases--while making commonly treatable cases even easier--to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.About the University of Wisconsin School of Medicine and Public Health
The University of Wisconsin School of Medicine and Public Health is recognized as one of the nation's leading institutions in health sciences education, research, and service. Founded in 1907 as the medical school of the University of Wisconsin-Madison, in 2005 it became the nation's first school to integrate the disciplines of medicine and public health. With a deep commitment to a vision of healthy people and healthy communities, we translate discovery into application and interconnect clinical care, education and research. The school employs more than 5,600 faculty and staff and provides educational opportunities for nearly 3,000 students and postgraduate trainees. For federal fiscal year 2025, the school ranked #10 in the nation among public medical schools for NIH funding according to the Blue Ridge Institute for Medical Research. Some of the nation's leading researchers, educators, and clinicians are among the faculty, including several National Medal of Science recipients and National Academy of Science honorees.Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations related to the proposed collaboration between the Company and the University of Wisconsin. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to enter into a collaboration agreement with the University of Wisconsin, the ability to achieve the benefits of such collaboration, and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 28, 2025, and as updated periodically with the company's other filings with the SEC.Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.Media Contacts
Daniel Biank
Vice President of Regulatory & Government Affairs
Accuray
dbiank@accuray.comRobyn M. Perrin, Ph.D.
Chief Communications Officer
University of Wisconsin School of Medicine and Public Health
rmperrin@wisc.edu View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-and-the-university-of-wisconsin-madison-announce-master-research-agreement-to-improve-personalized-care-for-patients-with-cancer-302773750.htmlSOURCE Accuray Incorporated Original: Accuray and the University of Wisconsin-Madison Announce Master Research Agreement to Improve Personalized Care for Patients with Cancer

Accuray Reports Fiscal 2026 Third Quarter Financial ResultsMay 6, 2026 4:05 PM
PR Newswire (US) MADISON, Wis., May 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter ended March 31, 2026. Key HighlightsTransformation plan delivering ahead of expectations, with approximately $10 million of cost and margin improvements achieved through the fiscal third quarter, positioning the company to exceed the $12 million FY26 target.Commercial leadership strengthened with the appointment of Paul Miele as Chief Commercial Officer, bringing deep global experience in scaling capital medical device businesses and accelerating profitable growth.Strategic partnerships gaining momentum, expanding Accuray's ecosystem across imaging, software, workflow, clinical research, and operational execution in collaboration with many leading organizations to further amplify the company's strengths.Company withdraws fiscal 2026 financial guidance due to geopolitical uncertainty in the Middle East, which continues to materially impact product shipments and service revenue, with installations in several of the markets within the region delayed.At the upcoming European Society for Radiotherapy and Oncology ("ESTRO") Congress in Stockholm, Sweden on May 15 – 19, 2026, the Company will showcase a series of practical, customer-driven product enhancements that reinforce their commitment to clinical excellence, workflow efficiency, and continuous innovation."During the quarter, we made meaningful progress executing against the transformation plan we launched in December," said Steve LaNeve, President and Chief Executive Officer of Accuray. "We are already seeing tangible benefits from these initiatives, including approximately $10 million in realized margin improvements through the fiscal third quarter, positioning us ahead of our original expectations. We have also strengthened our leadership team with experienced talent in key strategic areas and continue to enhance our technology platform through highly strategic partnerships focused on advancing real-time adaptation to patient and tumor motion during treatment, a core differentiator of Accuray's technology. Taken together, we believe these actions will improve execution, strengthen profitability, and create meaningful long-term value for our shareholders."Mr. LaNeve continued, "Overall, we are encouraged by the progress we are making and remain confident in our strategy and our ability to execute on the areas within our control. However, the current geopolitical environment has created significant unpredictability around the timing of installations in several key Middle Eastern markets. Given these uncertainties, we believe it is prudent to withdraw financial guidance at this time, specifically as it relates to total net revenue and Adjusted EBITDA, and revisit our outlook when we report fiscal fourth quarter results."Fiscal Third Quarter ResultsTotal net revenue was $104.8 million in the third quarter of fiscal 2026, or a decrease of 7 percent, as compared to $113.2 million in the prior fiscal year third quarter. Product revenue was $49.7 million in the third quarter of fiscal 2026, or a decrease of 13 percent, as compared to $57.3 million in the prior fiscal year third quarter. Service revenue was $55.1 million in the third quarter of fiscal 2026, or a decrease of 1 percent, as compared to $55.9 million in the prior fiscal year third quarter.Total gross profit was $25.3 million in the third quarter of fiscal 2026, or 24.1 percent of total net revenue, as compared to a total gross profit of $31.6 million, or 27.9 percent of total net revenue, in the prior fiscal year third quarter. The decrease in gross margin rate was primarily due to higher net parts consumption of $3.2 million, as well as higher than average logistics and duties costs.Operating expenses were $34.4 million in the third quarter of fiscal 2026, or an increase of 12 percent, as compared to $30.6 million in the prior fiscal year third quarter. Operating expenses in the third quarter of fiscal 2026 include $6.5 million in restructuring charges. Excluding restructuring charges, operating expenses would have decreased by $2.8 million, or 9 percent, as compared to the prior fiscal year third quarter. Additionally, the prior year third quarter benefited from a $3.2 million reversal of accrued compensation from the first half of fiscal year 2025. Adjusting for these two discrete items, third quarter 2026 operating expenses decreased $6.0 million, or 18%, versus prior year.Net loss was $11.8 million in the third quarter of fiscal 2026, or a diluted net loss of $0.09 per share, as compared to a net loss of $1.3 million, or a diluted net loss of $0.01 per share, in the prior fiscal year third quarter. Adjusted EBITDA was $3.8 million in the third quarter of fiscal 2026, as compared to an adjusted EBITDA of $6.0 million in the prior fiscal year third quarter.Gross product orders were $48.5 million in the third quarter of fiscal 2026 as compared to $71.2 million in the prior fiscal year third quarter. The book to bill ratio was 1.0 in the third quarter of fiscal 2026, as compared to 1.2 the prior fiscal year third quarter. Order backlog as of March 31, 2026 was $356.2 million, which is approximately 21% percent lower than at the end of the prior fiscal year third quarter.Total cash, cash equivalents and restricted cash as of quarter end amounted to $44.4 million compared to $47.9 million at the end of last fiscal quarter and compared to $62.1 million at June 30, 2025.First Nine Months ResultsTotal net revenue was $301.0 million in the first nine months of fiscal 2026, or a decrease of 9 percent, as compared to $331.0 million in the prior fiscal year period. Product revenue was $131.9 million in the first nine months of fiscal 2026, or a decrease of 21 percent, as compared to $166.9 million in the prior fiscal year period. Service revenue was $169.1 million in the first nine months of fiscal 2026, or an increase of 3 percent, as compared to $164.1 million in the prior fiscal year period.Total gross profit was $76.4 million in the first nine months of fiscal 2026, or 25.4 percent of total net revenue, as compared to a total gross profit of $108.0 million, or 32.6 percent of total net revenue, in the prior fiscal year period.Operating expenses were $108.3 million in the first nine months of fiscal 2026, or an increase of 4 percent, as compared to $104.4 million in the prior fiscal year period. Operating expenses in the first nine months of fiscal 2026 include $15.4 million in restructuring charges. Excluding restructuring charges, operating expenses would have decreased by $11.5 million, or 11% percent as compared to the prior fiscal year period.Net loss was $47.3 million in the first nine months of fiscal 2026, or a diluted net loss of $0.39 per share, as compared to a net loss of $2.7 million, or a diluted net loss of $0.03 per share, in the prior fiscal year period. Adjusted EBITDA was a negative $2.3 million in the first nine months of fiscal 2026, as compared to a positive adjusted EBITDA of $18.8 million in the prior fiscal year period.Gross product orders was $154.2 million in the first nine months of fiscal 2026 as compared to $203.3 million in the prior fiscal year period. The book to bill ratio was 1.2 in the first six months of fiscal 2026, as compared to 1.2 in the prior fiscal year period. Conference Call InformationAccuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the third quarter of fiscal 2026 as well as recent corporate developments. Conference call dial-in information is as follows:U.S. callers: (833) 316-0563International callers: (412) 317-5747Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (855) 669-9658 (USA), or (412) 317-0088 (International), Conference ID: 4178502. An archived webcast will also be available on Accuray's website until Accuray announces its results for the fourth quarter of fiscal 2026.Use of Non-GAAP Financial MeasuresAccuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, and (gain) loss from change in fair value of warrant liability ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.About AccurayAccuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.Forward-Looking StatementsStatements made in this press release that are not statements of historical fact are forward-looking statements that are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's future results of operations and financial position, including expectations regarding: the company's backlog, age-ins and age-outs, cancellations of contracts and foreign currency impacts; the anticipated drivers of the company's future capital requirements; expectations of the company's strategy in China and the company's China joint venture as well as its expected impact on the company's business; expectations regarding the market in China for radiation oncology systems; expectations regarding the effects of the global macroeconomic conditions on the company's financial results and business as well as the business of the company's customers and suppliers; expectations regarding the impact of changes in government administration policy positions; expectations regarding delays in deliveries and installations and its impact on the company's business; expectations regarding inflation, supply chain challenges and heightened logistics costs and its impact on the company's business, including gross margins and net income (loss); expectations regarding the timing of deliveries and revenue conversion; the company's expectations regarding the adequacy of its manufacturing facilities; the anticipated risks associated with the company's foreign operations and fluctuations in the U.S. Dollar and foreign currencies as well as its ability to mitigate such risks; potential changes in tariffs, export controls, trade sanctions and other trade policies; expectations related to the company's convertible notes and credit facilities; expectations related to the company's leases; the sufficiency of the company's cash, cash equivalents and investments to meet the company's anticipated cash needs for working capital and capital expenditures and the company's business strategy, plans and objectives; the expected benefits from the transformation plan, including expected improvement in annualized operating profit and cost and margin improvements; the ability to achieve the objectives of the transformation plan; expected restructuring charges for fiscal year 2026; the company's ability to deliver sustained performance and execute on its strategies and objectives, including related to its transformation efforts and restructuring plans; the company's ability to improve sales and drive margin expansion; opportunities to accelerate top-line growth and expand profitability; expectations related to management, including the new chief commercial officer; expectations regarding the impact of tariffs as well as mitigation efforts by the company; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding installed base growth; and the company's ability to improve execution, drive sustainable, profitable growth, while creating long-term value for patients, providers and shareholders. Forward-looking statements generally can be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects," "may," "will be," "will continue," "will likely result," and similar expressions. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; effects related to international tariffs; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; geopolitical uncertainty, including armed conflict or political instability in the Middle East or other regions in which the company or its customers operate, and the effect of such conditions on the timing of system installations, customer site readiness, service revenue recognition, and the ability to complete transactions in affected markets; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 17, 2026, and as updated periodically with the company's other filings with the SEC.Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.Aman Patel, CFASteve MonroeInvestor Relations, ICR-WestwickeVice President, Financial Planning & Analysis - Accurayinvestor.relations@accuray.cominvestor.relations@accuray.comFinancial Tables to FollowAccuray IncorporatedCondensed Consolidated Statements of Operations(in thousands, except per share data)(Unaudited)


Three Months Ended

Nine Months Ended


March 31,

March 31,


2026

2025

2026

2025
Net revenue:















Products
$49,714

$57,320

$131,880

$166,878
Services

55,131


55,923


169,148


164,084
Total net revenue

104,845


113,243


301,028


330,962
Cost of revenue:















Cost of products

38,829


44,301


104,402


111,315
Cost of services

40,722


37,315


120,249


111,659
Total cost of revenue

79,551


81,616


224,651


222,974
Gross profit

25,294


31,627


76,377


107,988
Operating expenses:















Research and development

8,178


10,712


30,046


36,472
Selling and marketing

8,439


9,110


28,986


31,906
General and administrative

11,225


10,758


33,886


36,005
Restructuring

6,539


—


15,425


—
Total operating expenses

34,381


30,580


108,343


104,383
Income (loss) from operations

(9,087)


1,047


(31,966)


3,605
Income from equity method investment, net

408


2,297


1,318


3,829
Interest expense

(8,446)


(2,890)


(24,207)


(8,728)
Gain from change in fair value of warrant liability

3,359


—


7,198


—
Other income (expense), net

2,429


(1,294)


1,916


357
Loss before provision for income taxes

(11,337)


(840)


(45,741)


(937)
Provision for income taxes

468


457


1,512


1,777
Net loss
$(11,805)

$(1,297)

$(47,253)

$(2,714)
Net loss per share - basic and diluted
$(0.09)

$(0.01)

$(0.39)

$(0.03)
Weighted average common shares used in computing net loss per
share:















Basic and diluted

124,304


102,825


121,396


101,462
 Accuray IncorporatedCondensed Consolidated Balance Sheets(in thousands)(Unaudited)


March 31, 2026

June 30, 2025
Assets







Current assets:







Cash and cash equivalents

38,067

$57,416
Restricted cash

467


574
Accounts receivable, net

64,573


83,192
Inventories, net

156,626


141,020
Prepaid expenses and other current assets

33,463


33,501
Deferred cost of revenue

20


1,762
Total current assets

293,216


317,465
Property and equipment, net

29,002


28,658
Investment in joint venture

6,321


4,612
Operating lease right-of-use assets, net

28,898


33,115
Goodwill

57,882


57,802
Long-term restricted cash

5,909


4,144
Other assets

26,374


24,443
Total assets
$447,602

$470,239
Liabilities and stockholders' equity







Current liabilities:







Accounts payable
$52,805

$34,033
Accrued compensation

16,972


14,573
Operating lease liabilities, current

8,228


7,375
Other accrued liabilities

26,370


29,361
Customer advances

11,365


12,197
Deferred revenue

78,944


82,306
Short-term debt

11,160


12,734
Total current liabilities

205,844


192,579
Operating lease liabilities, non-current

28,989


32,482
Long-term other liabilities

6,925


5,160
Warrant liability

3,119


8,497
Deferred revenue, non-current

26,998


26,566
Long-term debt

134,020


123,786
Total liabilities

405,895


389,070
Stockholders' equity:







Common stock

119


113
Additional paid-in capital

610,784


602,165
Accumulated other comprehensive loss

(2,671)


(1,837)
Accumulated deficit

(566,525)


(519,272)
Total stockholders' equity

41,707


81,169
Total liabilities and stockholders' equity
$447,602

$470,239
 Accuray IncorporatedSummary of Orders and Backlog(in thousands, except book to bill ratio)(Unaudited)


Three Months Ended

Nine Months Ended


March 31,

March 31,


2026

2025

2026

2025
Gross orders
$48,524

$71,167

$154,158

$203,294
Net orders
$22,604

$46,656

$61,144

$131,951
Order backlog
$356,235

$452,392

$356,235

$452,392
Book to bill ratio (a)

1.0


1.2


1.2


1.2
(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period. Accuray IncorporatedReconciliation of GAAP Net Loss to Adjusted EBITDA(in thousands)(Unaudited)


Three Months Ended

Nine Months Ended


March 31,

March 31,


2026

2025

2026

2025
GAAP net loss
$(11,805)

$(1,297)

$(47,253)

$(2,714)
Depreciation and amortization (a)

2,078


1,575


5,917


4,552
Stock-based compensation

1,378


2,745


4,775


7,383
Interest expense, net (b)

8,265


2,568


23,508


7,825
Provision for income taxes

468


457


1,512


1,777
Gain from change in fair value of warrant liability

(3,359)


—


(7,198)


—
Restructuring charges

6,539


—


15,425


—
Post-financing costs

199


—


1,031


—
Adjusted EBITDA
$3,763

$6,048

$(2,283)

$18,823
(a) Consists of depreciation on property and equipment and amortization of capitalized software and intangibles.(b) Consists of interest expense net of interest income.  View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2026-third-quarter-financial-results-302764579.htmlSOURCE Accuray Incorporated Original: Accuray Reports Fiscal 2026 Third Quarter Financial Results

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026April 22, 2026 4:05 PM
PR Newswire (US)

MADISON, Wis., April 22, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.







The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.htmlSOURCE Accuray Incorporated

Original: Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial OfficerApril 6, 2026 9:00 AM
PR Newswire (US)

MADISON, Wis., April 6, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY), a leading provider of radiation therapy systems for cancer treatment, today announced the appointment of Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026. Miele will join Accuray's executive leadership team and lead the company's global commercial organization as Accuray continues to advance its transformation and strengthen execution across its portfolio.







"Paul brings deep global commercial leadership experience and a strong track record of driving transformation and sales growth in complex medical technology businesses," said Steve La Neve, President and Chief Executive Officer of Accuray. "His background in rebuilding commercial operating models, accelerating capital equipment and services sales, and unlocking recurring revenue opportunities will  be instrumental as we continue to strengthen our commercial performance and position Accuray for long-term value creation."Mr. Miele is a seasoned commercial executive with nearly two decades of experience leading and scaling global capital medical device businesses across the Americas, EMEA, and APAC. Most recently, Mr. Miele served as Business Unit Leader and General Manager for the MONARCH™ robotic platform at Johnson & Johnson MedTech, where he was recruited to lead a commercial turnaround. In that role, he rebuilt the commercial operating model, reactivated the installed base, strengthened service and solutions monetization, and accelerated capital equipment sales, reversing a revenue decline trend and generating double digit percentage annual sales growth during his tenure. Prior to Monarch, Mr. Miele was similarly successful in senior commercial roles at Globus Medical and Intuitive Surgical.As Chief Commercial Officer, Mr. Miele will be responsible for defining and executing Accuray's global commercialization strategy across sales, marketing, pricing and market access, commercial partnerships, and launch excellence."Accuray has a strong foundation of innovation, a large installed base, a group of dedicated distribution partners, and a meaningful opportunity to further strengthen its commercial impact worldwide," said Paul Miele. "Most importantly, Accuray's products are vital to treating cancer patients in 70+ countries around the world. I'm excited to join the team and help drive growth in systems and services sales, with a particular focus on marketing and selling value-added solutions to our customers, on commercial execution, and on carrying out Accuray's mission for the benefit of countless customers and patients."About AccurayAccuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expectations regarding the Company's new Chief Commercial Officer and ability to strengthen commercial performance. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 17, 2026, and as updated periodically with the company's other filings with the SEC.Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.Media Contact
Steve Monroe     
Vice President, Financial Planning & Analysis - Accuray 
smonroe@accuray.comInvestor Contact
Aman Patel, CFA
Investor Relations, ICR-Westwicke
aman.patel@westwicke.com 



View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-appoints-paul-miele-as-senior-vice-president-and-chief-commercial-officer-302733399.htmlSOURCE Accuray Incorporated

Original: Accuray Appoints Paul Miele as Senior Vice President and Chief Commercial Officer

ARAY......................................a/h

Accuray Reports Fiscal 2026 Second Quarter Financial ResultsFebruary 4, 2026 4:05 PM
PR Newswire (US)

MADISON, Wis., Feb. 4, 2026 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2025.







Key Highlights On December 15, 2025 the Company announced the first phase of comprehensive, strategic, operational, and organizational transformational plan, which is expected to improve annualized operating profitability by approximately $25 million and set the stage for revenue growth:Plan includes organizational realignment, rightsizing of cost structure, outsourcing, and sales enablement in order to enhance competitiveness and support long-term strategy.Workforce optimization actions will affect approximately 15% of the company's employees globally.Of the expected $25 million in annualized operating profit improvement, approximately $12 million is expected to be realized in fiscal year 2026.During the second quarter of fiscal 2026, in connection with the transformational plan, the Company initiated a restructuring plan aimed at reducing costs, aligning resources with strategic priorities, and streamlining operations. The Company recorded $6.1 million in restructuring charges, which included $4.1 million in severance related costs, $0.7 million in implementation and other costs, and $1.2 million in impairments that were directly related to the restructuring plan. We expect total restructuring charges to be approximately $13 million for fiscal year 2026."Over the past 90 days, I've met extensively with Accuray teams and customers across all major regions. Their insights have directly informed the decisive actions we've already taken — from reorganizing our commercial structure to refining our near-term product and service investment priorities. We moved quickly and with discipline across the four pillars we outlined publicly: commercial simplification, global functional alignment, elevation of service and product development, and cost-structure and footprint optimization," said CEO Steve La Neve."While this transformation is in its early stages, the pace of execution, the alignment across the organization, and the level of accountability give me confidence that we are on the right trajectory. Our objectives remain clear: accelerate top-line growth, enhance our competitive position, expand profitability, and deliver sustainable long-term value for all of our stakeholders, building a stronger Accuray, and the momentum we are seeing reinforces the impact of the steps taken to date," added La Neve.Fiscal Second Quarter ResultsTotal net revenue was $102.2 million in the second quarter of fiscal 2026, or a decrease of 12 percent, as compared to $116.2 million in the prior fiscal year second quarter. Product revenue was $45.0 million in the second quarter of fiscal 2026, or a decrease of 26 percent, as compared to $61.2 million in the prior fiscal year second quarter. Service revenue was $57.2 million in the second quarter of fiscal 2026, or an increase of 4 percent, as compared to $55.0 million in the prior fiscal year second quarter.Total gross profit was $24.1 million in the second quarter of fiscal 2026, or 23.5 percent of total net revenue, as compared to a total gross profit of $41.9 million, or 36.1 percent of total net revenue, in the prior fiscal year second quarter. The decrease in the gross profit and gross margin rate was primarily due to geographical sales mix and the China joint venture delivering less systems to its end customers in the second quarter of fiscal year 2026 as compared to the prior fiscal year second quarter.Operating expenses was $35.6 million in the second quarter of fiscal 2026, or a decrease of 4 percent, as compared to $37.2 million in the prior fiscal year second quarter. Operating expenses in the second quarter of fiscal 2026 include $6.1 million in restructuring charges. Excluding restructuring charges, operating expenses would have decreased by $7.6 million, or 20 percent, as compared to the prior fiscal year second quarter.Net loss was $13.8 million in the second quarter of fiscal 2026, or a diluted net loss of $0.11 per share, as compared to a net income of $2.5 million, or a diluted net income of $0.02 per share, in the prior fiscal year second quarter. Adjusted EBITDA was a negative $1.9 million in the second quarter of fiscal 2026, as compared to a positive adjusted EBITDA of $9.6 million in the prior fiscal year second quarter.Gross product orders were $66.1 million in the second quarter of fiscal 2026 as compared to $76.8 million in the prior fiscal year second quarter. The book to bill ratio was 1.5 in the second quarter of fiscal 2026, as compared to 1.3 the prior fiscal year second quarter. Order backlog as of December 31, 2025 was $383.3 million, which is approximately 17% percent lower than at the end of the prior fiscal year second quarter.Cash, cash equivalents, and short-term restricted cash were $41.9 million as of December 31, 2025, a decrease of $16.1 million from June 30, 2025.Fiscal Six Months ResultsTotal net revenue was $196.2 million in the first six months of fiscal 2026, or a decrease of 10 percent, as compared to $217.7 million in the prior fiscal year period. Product revenue was $82.2 million in the first six months of fiscal 2026, or a decrease of 25 percent, as compared to $109.6 million in the prior fiscal year period. Service revenue was $114.0 million in the first six months of fiscal 2026, or an increase of 5 percent, as compared to $108.2 million in the prior fiscal year period.Total gross profit was $51.1 million in the first six months of fiscal 2026, or 26.0 percent of total net revenue, as compared to a total gross profit of $76.4 million, or 35.1 percent of total net revenue, in the prior fiscal year period.Operating expenses was $74.0 million in the first six months of fiscal 2026, as compared to $73.8 million in the prior fiscal year period. Operating expenses in the first six months of fiscal 2026 include $8.9 million in restructuring charges. Excluding restructuring charges, operating expenses would have decreased by $8.7 million, or 12% percent as compared to the prior fiscal year period.Net loss was $35.4 million in the first six months of fiscal 2026, or a diluted net loss of $0.30 per share, as compared to a net loss of $1.4 million, or a diluted net loss of $0.01 per share, in the prior fiscal year period. Adjusted EBITDA was negative at $6.0 million in the first six months of fiscal 2026, as compared to a positive adjusted EBITDA of $12.8 million in the prior fiscal year period.Gross product orders was $105.6 million in the first six months of fiscal 2026 as compared to $132.1 million in the prior fiscal year period. The book to bill ratio was 1.3 in the first six months of fiscal 2026, as compared to 1.2 in the prior fiscal year period. Fiscal Year 2026 Financial GuidanceThe Company is updating its guidance for fiscal year 2026 as follows:Total net revenue is expected in the range of $440 million to $450 million.Adjusted EBITDA is expected in the range of $22 million to $25 million.Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, provision for income taxes, (gain) loss from change in fair value of warrant liability, and certain non-recurring, irregular and one-time items. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.Conference Call InformationAccuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the second quarter of fiscal 2026 as well as recent corporate developments. Conference call dial-in information is as follows:U.S. callers: (833) 316-0563International callers: (412) 317-5747Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (855) 669-9658 (USA), or (412) 317-0088 (International), Conference ID: 8587254. An archived webcast will also be available on Accuray's website until Accuray announces its results for the third quarter of fiscal 2026.Use of Non-GAAP Financial MeasuresAccuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, and (gain) loss from change in fair value of warrant liability ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.About AccurayAccuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total net revenue and adjusted EBITDA; the expected benefits from the transformation plan, including expected improvement in annualized operating profit; the ability to achieve the objectives of the transformation plan; expected restructuring charges for fiscal year 2026; the company's ability to deliver sustained performance and execute on its strategies and objectives, including related to its transformation efforts and restructuring plans; the company's ability to expand adjusted EBITDA margins as a percentage of revenue; expectations regarding the company's adjusted EBITDA margin run-rate; opportunities to accelerate top-line growth and expand profitability; the appointment of a new global chief commercial officer; expectations regarding the impact of tariffs as well as mitigation efforts by the company; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; expectations regarding the company's China joint venture; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding installed base growth; and the company's ability to drive sustainable, profitable growth, while creating long-term value for patients, providers and shareholders. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 5, 2025, and as updated periodically with the company's other filings with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.Aman Patel, CFASteve MonroeInvestor Relations, ICR-WestwickeVice President, Financial Planning & Analysis - Accurayaman.patel@westwicke.comsmonroe@accuray.com Financial Tables to Follow Accuray IncorporatedCondensed Consolidated Statements of Operations(in thousands, except per share data)(Unaudited)








Three Months Ended

Six Months Ended


December 31,

December 31,


2025

2024

2025

2024
Net revenue:















Products
$45,005

$61,189

$82,166

$109,558
Services

57,236


54,985


114,017


108,161
Total net revenue

102,241


116,174


196,183


217,719
Cost of revenue:















Cost of products

36,151


34,553


65,573


67,014
Cost of services

42,018


39,729


79,527


74,344
Total cost of revenue

78,169


74,282


145,100


141,358
Gross profit

24,072


41,892


51,083


76,361
Operating expenses:















Research and development

10,650


13,644


21,868


25,760
Selling and marketing

8,848


11,114


20,547


22,796
General and administrative

10,065


12,427


22,661


25,247
Restructuring

6,075


—


8,886


—
Total operating expenses

35,638


37,185


73,962


73,803
Income (loss) from operations

(11,566)


4,707


(22,879)


2,558
Income from equity method investment, net

471


1,604


910


1,532
Interest expense

(7,709)


(2,883)


(15,761)


(5,838)
   Gain from change in fair value of warrant liability

5,713


—


3,839




   Other (expense) income, net

(106)


(196)


(513)


1,651
Income (loss) before provision for income taxes

(13,197)


3,232


(34,404)


(97)
Provision for income taxes

573


695


1,044


1,320
Net income (loss)
$(13,770)

$2,537

$(35,448)

$(1,417)
Net income (loss) per share - basic
$(0.11)

$0.03

$(0.30)

$(0.01)
Net income (loss) per share - diluted
$(0.11)

$0.02

$(0.30)

$(0.01)
Weighted average common shares used in computing net loss per
share:















Basic

120,973


101,405


119,968


100,796
Diluted

120,973


103,746


119,968


100,796
 Accuray IncorporatedCondensed Consolidated Balance Sheets(in thousands)(Unaudited)


December 31,
2025

June 30, 2025
Assets







Current assets:







Cash and cash equivalents

41,295

$57,416
Restricted cash

575


574
Accounts receivable, net

60,962


83,192
Inventories, net

150,962


141,020
Prepaid expenses and other current assets

36,968


33,501
Deferred cost of revenue

1,626


1,762
Total current assets

292,388


317,465
Property and equipment, net

29,256


28,658
Investment in joint venture

5,804


4,612
Operating lease right-of-use assets, net

30,807


33,115
Goodwill

57,849


57,802
Long-term restricted cash

5,999


4,144
Other assets

25,906


24,443
Total assets
$448,009

$470,239
Liabilities and stockholders' equity







Current liabilities:







Accounts payable
$43,519

$34,033
Accrued compensation

14,925


14,573
Operating lease liabilities, current

8,155


7,375
Other accrued liabilities

30,902


29,361
Customer advances

11,850


12,197
Deferred revenue

78,978


82,306
Short-term debt

11,110


12,734
Total current liabilities

199,439


192,579
Operating lease liabilities, non-current

30,184


32,482
Long-term other liabilities

6,101


5,160
Warrant liability

6,478


8,497
Deferred revenue, non-current

27,610


26,566
Long-term debt

124,777


123,786
Total liabilities

394,589


389,070
Stockholders' equity:







Common stock

119


113
Additional paid-in capital

609,409


602,165
Accumulated other comprehensive loss

(1,388)


(1,837)
Accumulated deficit

(554,720)


(519,272)
Total stockholders' equity

53,420


81,169
Total liabilities and stockholders' equity
$448,009

$470,239
 Accuray IncorporatedSummary of Orders and Backlog(in thousands, except book to bill ratio)(Unaudited)








Three Months Ended

Six Months Ended


December 31,

December 31,


2025

2024

2025

2024
Gross orders
$66,064

$76,762

$105,634

$132,127
Net orders

32,611


55,639


38,526


85,295
Order backlog

383,332


463,056


383,332


463,056
Book to bill ratio (a)

1.5


1.3


1.3


1.2

(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period. Accuray IncorporatedReconciliation of GAAP Net Income (Loss) to Adjusted EBITDA(in thousands)(Unaudited)








Three Months Ended

Six Months Ended


December 31,

December 31,


2025

2024

2025

2024
GAAP net income (loss)
$(13,770)

$2,537

$(35,448)

$(1,417)
Depreciation and amortization (a)

2,163


1,513


3,839


2,977
Stock-based compensation

882


2,284


3,397


4,638
Interest expense, net (b)

7,463


2,605


15,243


5,257
Provision for income taxes

573


695


1,044


1,320
(Gain) from change in fair value of warrant liability

(5,713)


—


(3,839)


—
Restructuring charges

6,075


—


8,886


—
Post-financing costs

391


—


832


—
Adjusted EBITDA
$(1,936)

$9,634

$(6,046)

$12,775

(a) Consists of depreciation on property and equipment and amortization of capitalized software and intangibles.(b) Consists of interest expense net of interest income. Accuray IncorporatedForward-Looking GuidanceReconciliation of Projected GAAP Net Loss to Projected Adjusted EBITDA(in thousands)(Unaudited)





Twelve Months Ending


June 30, 2026


From

To
GAAP net loss
$(39,000)

$(36,000)
Depreciation and amortization (a)

8,500


8,500
Stock-based compensation

9,250


9,250
Interest expense, net (b)

30,000


30,000
Provision for income taxes

2,500


2,500
(Gain) from change in fair value of warrant liability

(4,000)


(4,000)
Restructuring charges

13,000


13,000
Post-financing costs

1,750


1,750
Adjusted EBITDA
$22,000

$25,000

(a) Consists of depreciation on property and equipment and amortization of capitalized software and intangibles.(b) Consists of interest expense net of interest income. 



View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2026-second-quarter-financial-results-302679353.htmlSOURCE Accuray Incorporated

Original: Accuray Reports Fiscal 2026 Second Quarter Financial Results

ARAY, new 52; week low

ARAY.................................................https://stockcharts.com/h-sc/ui?s=ARAY&p=W&b=5&g=0&id=p86431144783

ARAY under $2

ARAY new 52 low

ARAY new 52 lo

RECEIVED FDA CLEARANCE!

Accuray Inc NASDAQ: ARAY

GoSymbol lookup
Health Care : Health Care Equipment & Supplies | Small Cap BlendCompany profile
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
New 52 week high
Accuray Inc NASDAQ: ARAY

GoSymbol lookup
Health Care : Health Care Equipment & Supplies | Small Cap BlendCompany profile
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
New 52 week high

Accuray Inc NASDAQ: ARAY

GoSymbol lookup
Health Care : Health Care Equipment & Supplies | Small Cap BlendCompany profile
Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.
New 52 week high

Aray comes out with earnings and still no one post on this board. What is everyone doing that keeps you off this board?

You asked where everyone went... Check out the boards for RDGL

Not sure what the meaning of your message is.

RDGL / Vivos

Wow, last post on here 02/2021. Where is everyone?

ACCURAY INC: WHITTERS JOSEPH E (Director) Buys 20,000 @ Avg Price: $5.02 (Form4)

First Quarter Fiscal 2021 Summary

Net revenue of $85.3 million, operating income of $5.5 million
Adjusted EBITDA grew to $9 million from a loss of $1 million in the prior year first quarter
Gross orders of $50.5 million, ending backlog of $597.3 million, an increase of 21 percent from September 30, 2019

Other Recent Operational Highlights

Expect revenue recognition for China Type A systems previously awarded in October 2019 to start in the second quarter of fiscal 2021
Introduced ClearRT™ Helical kVCT Imaging for the Radixact System at ASTRO 2020
44 clinical abstracts related to customer clinical experience on CyberKnife and TomoTherapy/Radixact exhibited at ASTRO 2020 Scientific Sessions

"We are off to a solid start in fiscal 2021 despite the headwinds created by the COVID-19 environment. Our global team continues to adapt and make the necessary adjustments to compete and operate effectively given the current market conditions and delivered the fourth consecutive quarter of operating profit, said Joshua H. Levine, President and CEO of Accuray. "Looking ahead, we will be focused on driving the revenue conversion process related to the China Type A systems beginning in the second quarter. Concurrent with this year's recent ASTRO meeting, we have received very positive customer feedback related to the introduction of our ClearRT™ Helical kVCT imaging upgrade for the Radixact System as we drive our long-term strategic commitment to continued innovation."

Q1 Fiscal 2021 Financial Highlights

Gross product orders totaled $50.5 million for the first quarter of fiscal 2021 compared to $78.5 million for the prior fiscal year first quarter. Order backlog as of September 30, 2020 was $597.3 million, approximately 21 percent higher than at the end of the prior fiscal year first quarter.

Total net revenue was $85.3 million for the first quarter of fiscal 2021 compared to $89.6 million for the prior fiscal year first quarter. Product revenue totaled $31.3 million for the first quarter of fiscal 2021 compared to $37.6 million for the prior fiscal year first quarter, while service revenue totaled $54.1 million for the first quarter of fiscal 2021 compared to $52.0 million for the prior fiscal year first quarter.

Total gross profit for the first quarter of fiscal 2021 was $35.4 million or approximately 41.5 percent of total net revenue, comprised of product gross margin of 41.1 percent of product net revenue and service gross margin of 41.7 percent of service net revenue. This compares to total gross profit of $32.9 million or 36.8 percent of total net revenue, comprised of product gross margin of 42.6 percent of product net revenue and service gross margin of 32.5 percent of service net revenue for the prior fiscal year first quarter.

Net income was $0.4 million, or $0.0 per share, for the first quarter of fiscal 2021, compared to a net loss of $9.4 million, or a loss of $0.11 per share, for the prior fiscal year first quarter.

Adjusted EBITDA for the first quarter of fiscal 2021 was a positive $9.0 million, compared to a negative $1.0 million for the prior fiscal year first quarter.

Cash, cash equivalents, and short-term restricted cash were $95.5 million as of September 30, 2020, a decrease of $13.1 million from June 30, 2020 primarily due to a $10 million prepayment in principal with respect to our long-term debt.

Financial Guidance

The impact of the COVID-19 pandemic on Accuray's fiscal 2021 results remains uncertain. Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to refrain from providing financial guidance for fiscal year 2021.

On October 26, 2020, Accuray Incorporated (the “Company”) will be hosting an Analyst & Investor Virtual Meeting (the “Investor Meeting”) in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. The Investor Meeting will take place virtually and begin at 1:00pm ET (10:00am PT) and can be viewed live at https://www.accuray.com/investor-day-2020-rsvp/. A replay of the webcast will be available on the investor relations portion of the Company’s website within 24 hours of the conclusion of the presentation.

CMS 'pouring fuel on the fire' for Accuray with APM rule, says Lake Street 09:18 ARAY Lake Street analyst Brooks O'Neil said he believes Accuray is "exceptionally well-positioned to win" as healthcare markets globally stabilize after the COVID-19 pandemic, adding that CMS "is pouring fuel on the fire" by publishing a final rule related to an Alternate Payment Model now set to begin in 30% of the U.S. on January 1, 2021. The CMS rule will reward providers who utilize the high intensity, low frequency treatments pioneered by Accuray, according to O'Neil, who also sees the company as "on the cusp of the incredible opportunity to begin to deliver both Type A and Type B equipment to the massive China market over the next several quarters." O'Neil keeps a Buy rating and $10 price target on Accuray shares.

Read more at:
https://thefly.com/n.php?id=3166628

This was from Monday 9/28/20

big block at 2.46, now 2.55

* * $ARAY Video Chart 01-30-2020 * *

Link to Video - click here to watch the technical chart video

* * $ARAY Video Chart 01-22-2020 * *

Link to Video - click here to watch the technical chart video

* * $ARAY Video Chart 01-21-2020 * *

Link to Video - click here to watch the technical chart video

News: $ARAY Accuray To Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on August 15, 2019

SUNNYVALE, Calif. , July 19, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its fourth quarter and fiscal year 2019 ended June 30, 2019 on Thursday, August 15, 2019 after the market close. Management will host a conference call to review the res...

Read the whole news Accuray To Report Fiscal 2019 Fourth Quarter and Full Year Financial Results on August 15, 2019

News: $ARAY Accuray Launches Synchrony® Motion Tracking and Correction Technology for the Radixact® System

SUNNYVALE, Calif. , April 24, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the launch of its Synchrony ® motion tracking and correction technology 1  to be used with the Radixact ® System . This new feature adds intrafraction motion synch...

In case you are interested https://marketwirenews.com/news-releases/accuray-launches-synchrony-xae-motion-tracking-and-correction-technology-for-the-radixact-xae-system-8048882.html

* * $ARAY Video Chart 01-23-2019 * *

Link to Video - click here to watch the technical chart video

* * $ARAY Video Chart 10-31-18 * *

Link to Video - click here to watch the technical chart video

Huge News! "Mercy Advances Cancer Care in Missouri with Multi-System, Multi-Hospital Agreement for Accuray Radiation Therapy Systems". It is clear ARAY is the real deal! They have gained traction. Great public reference from the customer thereby arming their sales force. I would bet and am betting the sales pipeline is large and they are in the close cycle on many deals. This news will push many new customers to sign on the dotted line. You can not overestimate the significance of this news. It will translate to $$$.

* * $ARAY Video Chart 05-01-18 * *

Link to Video - click here to watch the technical chart video

This finding would seem support radio therapy and especially radio surgery (CyberKnife) as a more viable (as well as much less invasive) option to actual surgery as the preferred treatment protocol. Problem: Physicians fees for radio surgery are much less than for actual surgery. What do you think this means in terms of physician referrals and treatment advice? Exactly.

https://www.usatoday.com/story/news/2018/04/11/breast-cancer-surgery-healing-study/506525002/

This finding would seem support radio therapy and especially radio surgery (CyberKnife) as a more viable (as well as much less invasive) option to actual surgery as the preferred treatment protocol. Problem: Physicians fees for radio surgery are much less than for actual surgery. What do you think this means in terms of physician referrals and treatment advice? Exactly.

https://www.usatoday.com/story/news/2018/04/11/breast-cancer-surgery-healing-study/506525002/

Excellent earnings report. Looking for a big move by ARAY. JMO

ARAY big earnings news!
Accuray Fiscal Second Quarter Revenue Exceeds $100 Million and Increases 15 Percent Year-over-Year; Gross Orders of $77.9 Mil...

ARAY bullish 5.31

nasdaq stocks $1-10 with volume > 100,000

$ARAY recent news/filings

bullish 7.03
bull flag continuation
moving average support
moving average breakout

## source: finance.yahoo.com

Fri, 27 Nov 2015 12:03:55 GMT ~ Is Accuray Incorporated (ARAY) a Good Buy?


read full: http://www.insidermonkey.com/blog/is-accuray-incorporated-aray-a-good-buy-390968/
*********************************************************

Sat, 21 Nov 2015 18:25:37 GMT ~ Healthways, Inc. (HWAY): Are Hedge Funds Right To Leave This Stock?


read full: http://www.insidermonkey.com/blog/healthways-inc-hway-are-hedge-funds-right-to-leave-this-stock-385630/
*********************************************************

Fri, 20 Nov 2015 21:06:30 GMT ~ ACCURAY INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/151120/aray8-k.html
*********************************************************

Mon, 16 Nov 2015 21:32:00 GMT ~ SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Accuray Incorporated

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 16, 2015 / Levi & Korsinsky announces it has commenced an investigation of Accuray Incorporated (NASDAQGS: ARAY) concerning possible breaches of fiduciary duty by the ...

read full: http://finance.yahoo.com/news/shareholder-alert-levi-korsinsky-llp-213200757.html
*********************************************************

Fri, 13 Nov 2015 18:04:17 GMT ~ ACCURAY INC Financials


read full: http://finance.yahoo.com/q/is?s=aray
*********************************************************

$ARAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ARAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ARAY/company-info
Ticker: $ARAY
OTC Market Place: Not Available
CIK code: 0001138723
Company name: Accuray, Inc.
Incorporated In: DE, USA


$ARAY share structure

## source: otcmarkets.com

Market Value: $561,485,784 a/o Nov 27, 2015
Shares Outstanding: 79,869,955 a/o Oct 28, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$ARAY extra dd links

Company name: Accuray, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ARAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ARAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ARAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/news - http://finance.yahoo.com/q/h?s=ARAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ARAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ARAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ARAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accuray%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accuray%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accuray%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ARAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001138723&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ARAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ARAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ARAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ARAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ARAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ARAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ARAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ARAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ARAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ARAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ARAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ARAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ARAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ARAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ARAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ARAY



$ARAY DD Notes ~ http://www.ddnotesmaker.com/ARAY

Gap fill would be nice!!!! :)

Show time! Would like to see $9.5 by cristmass

$ARAY recent news/filings

bearish daytrade

## source: finance.yahoo.com

Mon, 11 May 2015 00:11:51 GMT ~ 10-Q for Accuray, Inc.


read full: http://www.companyspotlight.com/routers/headline/18143/10004/6514368?cp_code=YAH1&1431303111
*********************************************************

Thu, 07 May 2015 10:09:36 GMT ~ ACCURAY INC Files SEC form 10-Q, Quarterly Report


read full: http://biz.yahoo.com/e/150507/aray10-q.html
*********************************************************

Tue, 05 May 2015 17:40:05 GMT ~ Accuray Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog


read full: http://finance.yahoo.com/news/accuray-q3-loss-narrower-expected-174005306.html
*********************************************************

Tue, 05 May 2015 13:00:00 GMT ~ Accuray to Participate in the Bank of America Merrill Lynch 2015 Healthcare Conference

[PR Newswire] - A live webcast of the presentation will be available on the Investor Relations page of the Company's website at http://www.accuray.com/investors. The webcast replay of the presentation will begin approximately one hour after the conclusion of the live presentation and will be available for approximately 30 days.

read full: http://finance.yahoo.com/news/accuray-participate-bank-america-merrill-130000619.html
*********************************************************

Thu, 30 Apr 2015 22:36:19 GMT ~ Accuray slides in late trading after cutting revenue outlook


read full: http://sg.finance.yahoo.com/news/accuray-slides-trading-cutting-revenue-223619060.html
*********************************************************

$ARAY charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$ARAY company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/ARAY/company-info
Ticker: $ARAY
OTC Market Place: Not Available
CIK code: 0001138723
Company name: Accuray, Inc.
Incorporated In: CA, USA



$ARAY share structure

## source: otcmarkets.com

Market Value: $485,849,250 a/o May 13, 2015
Shares Outstanding: 78,489,378 a/o Jan 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$ARAY extra dd links

Company name: Accuray, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ARAY+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ARAY+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ARAY+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/news - http://finance.yahoo.com/q/h?s=ARAY+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ARAY/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ARAY+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ARAY
DTCC (dtcc.com): http://search2.dtcc.com/?q=Accuray%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Accuray%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Accuray%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ARAY
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001138723&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ARAY&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ARAY
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ARAY+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ARAY+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ARAY
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ARAY
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ARAY+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ARAY/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ARAY+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ARAY.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ARAY
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ARAY/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ARAY/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ARAY
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ARAY
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ARAY:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ARAY
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ARAY



$ARAY DD Notes ~ http://www.ddnotesmaker.com/ARAY

Hey grant!
not been on here in a while sorry buddy and onvo.. your welcome and blinkx reports Tuesday and I will look at that new stock you gave me! hope all is well..

Accuray rises premarket as 4Q orders improve
Accuray rises after company says radiation therapy system orders got better in 4th quarter

Associated PressAssociated Press – 1 hour 15 minutes ago

NEW YORK (AP) -- Shares of Accuray climbed in premarket trading Wednesday after the radiation-treatment equipment maker said new orders are improving.
Accuray reported its fiscal fourth-quarter results after the market closed on Tuesday. Its loss narrowed from a year ago despite a decline in revenue. Net new product orders rose 32 percent from last year, and the company said its backlog has grown over the last three months and is larger than it was a year ago.
Accuray shares picked up 50 cents, or 8.2 percent, to $6.60 in premarket trading.
The Sunnyvale, Calif., company sells radiation therapy systems under the names CyberKnife and TomoTherapy. Accuray said it took a loss of $18.7 million, or 25 cents per share, over the three months ended June 30. Accuray Inc. took a loss of $20.3 million, or 28 cents per share, a year earlier.
If one-time items are excluded the company said it lost 20 cents per share in the fourth quarters of fiscal 2013 and 2012. Revenue fell 16 percent, to $84.9 million from $100.5 million.
Analysts were expecting a loss of 20 cents per share on $84.3 million in revenue, according to FactSet.
Jefferies & Co. analyst Raj Denhoy said Accuray is moving in the right direction because orders are increasing and the company is getting better at keeping its costs under control. He kept a "Buy" rating on the stock and raised his price target to $8 per share from $6.50.
Accuray said it lost $103.2 million, or $1.41 per share, in fiscal 2013 after losing $72 million, or $1.02 per share, the year before. Revenue fell 23 percent, to $316 million from $409.2 million.
The company expects to report $325 million to $345 million in revenue in fiscal 2014. Analysts estimate $359.6 million on average.

~ $ARAY ~ Daily Par Sar Buy Signal ~ Criteria alert triggered during a recent trading session!

$ARAY has just triggered the "Parabolic SAR Buy Signals" scan criteria at Stockcharts.com
~ http://tinyurl.com/SAR-BUY ~







For a more in Depth study and DD profile, similar to the one contained in this link: ~ http://tinyurl.com/DDexample ~
Click the following link and type ticker or brief message asking me about the DD: ~ http://tinyurl.com/GET-THE-DD ~

What does the scan "Parabolic SAR Buy Signals" mean? Below is an image example and study link.
~ http://stockcharts.com/school/doku.php?id=chart_school:technical_indicators:parabolic_sar ~


To find other similar posts of "ARAY" utilize the links that follow.
Search MACDgyver's "Parabolic SAR Buy Signals" posts: ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ParSarBuyScan ~
Search MACDgyver's posts for symbol "ARAY": ~ http://investorshub.advfn.com/boards/msgsearchbymember.aspx?searchID=251916&srchyr=2013&SearchStr=ARAY ~
Search Ihub for "ARAY" posts: ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=ARAY ~


For more in depth training and information visit Chartschool on the Stockcharts page.
~ http://stockcharts.com/school/doku.php?id=chart_school ~


Also don't forget the Ihub Edu Channel.
~ http://investorshub.advfn.com/boards/education.aspx ~


c

7:02AM Accuray provides clarification on recently initiated voluntary recalls; no known injuries have been reported to date (ARAY) 4.44 : Co has voluntarily implemented a recall of two separate components from its CyberKnife product line: the Iris Variable Aperture Collimator and the RoboCouch Patient Positioning System. The affected parts are manufactured by third-party suppliers and are being removed from the system because they failed to meet the company's specifications and standards for quality. The co has notified impacted customers, and field service personnel have been deployed to apply the corrections should they be necessary. These recalls exclude the CyberKnife M6 Series Series. "We are pleased to report that no known injuries have been reported to date as a result of these issues."

5:11AM Accuray prices $100 mln of 3.50% convertible senior notes due 2018 (ARAY) 4.44 :

thanks... will take a look...

cheers,
grant